Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hybio Pharmaceutical Co., Ltd. (300199.SZ)
Shenzhen, CN
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.09% | -7.04% | +11.43% | +26.01% | +25.73% | +29.11% | +61.72% | +91.63% | +266.83% | +30.20% | +530.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+63.7% ★ Q1'26: -3.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+120.0% ★ Q1'26: +75.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.2% Q1'26: -2.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.8% ★ Q1'26: +53.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.5% Q1'26: +24.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.3% Q1'26: +4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.62× Q1'26: 2.81× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
768.26M
est: 923.00M (-16.8%)
|
855.05M
est: 923.00M (-7.4%)
|
1.25B
est: 855.60M (+45.7%)
|
1.26B
est: 1.14B (+10.6%)
|
614.19M
est: 1.60B (-61.6%)
|
721.72M
est: 2.12B (-65.9%)
|
735.97M
est: 2.64B (-72.1%)
|
704.32M
est: 770.00M (-8.5%)
|
431.38M
est: 610.00M (-29.3%)
|
590.20M
est: 590.00M (+0.0%)
|
966.35M
est: 1.10B (-12.1%)
|
1.52B
1.52B – 1.52B
+38.0% YoY
|
1.94B
1.94B – 1.94B
+27.9% YoY
|
| EBITDA |
434.15M
est: -222.63M (+295.0%)
|
442.45M
est: -222.63M (+298.7%)
|
476.25M
est: -206.37M (+330.8%)
|
307.53M
est: -275.79M (+211.5%)
|
-393.34M
est: -385.58M (-2.0%)
|
-440.71M
est: -511.11M (+13.8%)
|
-144.93M
est: -636.58M (+77.2%)
|
-52.60M
est: -185.72M (+71.7%)
|
-222.64M
est: -147.13M (-51.3%)
|
113.52M
est: -34.23M (+431.7%)
|
295.01M
est: -63.76M (+562.7%)
|
-88.01M
-88.01M – -88.01M
-38.0% YoY
|
-112.61M
-112.61M – -112.61M
-27.9% YoY
|
| EBIT |
351.73M
est: -424.06M (+182.9%)
|
351.53M
est: -424.06M (+182.9%)
|
379.79M
est: -393.10M (+196.6%)
|
210.90M
est: -525.32M (+140.1%)
|
-494.67M
est: -734.47M (+32.6%)
|
-545.25M
est: -973.58M (+44.0%)
|
-270.27M
est: -1.21B (+77.7%)
|
-182.13M
est: -353.77M (+48.5%)
|
-371.41M
est: -280.26M (-32.5%)
|
-32.41M
est: -162.11M (+80.0%)
|
162.27M
est: -301.96M (+153.7%)
|
-416.81M
-416.81M – -416.81M
-38.0% YoY
|
-533.31M
-533.31M – -533.31M
-27.9% YoY
|
| Net Income |
305.34M
est: 373.36M (-18.2%)
|
291.92M
est: 373.36M (-21.8%)
|
329.72M
est: 403.75M (-18.3%)
|
-340.78M
est: 333.68M (-202.1%)
|
-884.77M
est: 410.38M (-315.6%)
|
-609.43M
est: -43.41M (-1,303.8%)
|
30.81M
est: 681.78M (-95.5%)
|
-370.55M
est: -191.02M (-94.0%)
|
-513.88M
est: -425.45M (-20.8%)
|
-173.65M
est: -182.85M (+5.0%)
|
36.57M
est: 283.42M (-87.1%)
|
429.70M
429.70M – 429.70M
+51.6% YoY
|
594.26M
594.26M – 594.26M
+38.3% YoY
|
| SGA |
237.35M
est: 626.41M (-62.1%)
|
310.53M
est: 626.41M (-50.4%)
|
522.15M
est: 580.67M (-10.1%)
|
755.18M
est: 775.99M (-2.7%)
|
754.81M
est: 1.08B (-30.4%)
|
530.40M
est: 1.44B (-63.1%)
|
539.03M
est: 1.79B (-69.9%)
|
477.46M
est: 522.57M (-8.6%)
|
363.71M
est: 413.99M (-12.1%)
|
239.02M
est: 328.03M (-27.1%)
|
117.40M
est: 611.02M (-80.8%)
|
843.43M
843.43M – 843.43M
+38.0% YoY
|
1.08B
1.08B – 1.08B
+27.9% YoY
|
| EPS |
0.34
est: 0.43 (-20.9%)
|
0.33
est: 0.43 (-23.3%)
|
0.36
est: 0.47 (-22.6%)
|
-0.37
est: 0.38 (-196.3%)
|
-1.00
est: 0.47 (-311.6%)
|
-0.69
est: -0.05 (-1,280.0%)
|
0.03
est: 0.79 (-95.6%)
|
-0.42
est: -0.22 (-90.9%)
|
-0.58
est: -0.49 (-18.4%)
|
-0.20
est: -0.20 (+0.0%)
|
0.04
est: 0.31 (-87.1%)
|
0.47
0.47 – 0.47
+51.6% YoY
|
0.65
0.65 – 0.65
+38.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 776.3K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 231.7K | 0.29% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 53.2K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 23.6K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.63M | 0.06% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.97M | 0.05% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 33.8K | 0.39% |
| 8 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.00% | 1.5K | 0.44% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.2K | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 146.4K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baole Zhang | Vice President | — | male |
| Caiyun Bian | Accounting Supervisor | — | — |
| Honghong Tu | Vice President & Chief Financial Officer | — | male |
| Min Zhang | Vice President of HR, Corporate Management & Administrative Department | — | female |
| Shaogui Zeng | President & Chairman | — | male |
| Yu Liu | Vice President of Marketing | — | male |
| Yu Pinxiang | Executive President & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300199.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
